Prasterone (DHEA)

DRUG3 trials

Sponsors

EndoCeutics Inc., European Institute of Oncology

Conditions

Vaginal AtrophyVaginal Atrophy in Breast Cancer PatientsWomen With Breast Cancer

Phase 3

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

CompletedNCT02013544

EndoCeutics Inc.Vaginal Atrophy

Start: 2014-02-28End: 2015-02-28Updated: 2017-06-01

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

WithdrawnNCT03740945

EndoCeutics Inc.Vaginal Atrophy in Breast Cancer Patients

Start: 2018-11-06End: 2019-12-05Updated: 2020-07-31

Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer

Not yet recruitingNCT06611514

European Institute of OncologyWomen With Breast Cancer

Start: 2024-12-01End: 2027-01-01Target: 95Updated: 2024-11-19